Marksans Pharma Peer Comparison

NSE: MARKSANS | BSE: 524404

₹329.70

₹3.55 (1.09%)

As on 28-Aug-2026IST

Market cap

₹14,932 Cr

Revenue (TTM)

₹3,172 Cr

P/E Ratio

28.9

P/B Ratio

4.7

Div. Yield

0.3 %

Edit

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Market cap (₹ Cr)	14,932	9,704	31,434	13,940	2,746
Revenue (₹ Cr)	3,172	950	2,250	3,813	2,901
Net Profit (₹ Cr)	521.27	266.00	361.74	400.90	16.16
Net Margin (%)	15.92	27.44	15.77	10.30	0.55
RoE (%)	18.10	72.69	15.47	13.87	0.29
Price to Earnings	28.90	36.48	86.90	34.77	169.93
Price-To-Book	4.70	27.89	12.31	4.34	0.41

Income Statement (₹ Cr)

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Operating Revenue	2,950.94	878.40	2,192.49	3,510.50	2,711.50
Total Income	3,033.47	896.80	2,266.90	3,582.50	2,762.39
Total Expenditure	2,350.16	569.40	1,584.97	2,891.50	2,271.77
EBITDA	600.78	309.00	607.53	619.00	439.73
Depreciation	98.63	11.70	166.86	126.40	293.74
EBIT	502.15	297.30	440.67	492.60	145.99
Interest	24.13	2.00	40.88	19.30	159.46
Other Income	82.53	18.40	74.40	72.00	50.89
Exceptional Items	--	6.60	-8.00	-20.30	-18.11
Profit before Tax	560.56	320.30	466.19	525.00	19.31
Provision for Tax	140.49	80.20	117.28	123.90	16.07
Profit after Tax	420.06	240.10	348.91	401.10	3.24

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Shareholder's Funds	3,023.16	384.00	2,483.69	3,138.70	5,831.52
Minority Interest	29.52	--	--	--	--
Non-Current Liabilities	268.17	229.90	321.65	318.60	2,230.03
Current Liabilities	527.09	128.40	904.59	1,086.20	1,924.79
Total Liabilities	3,855.82	750.80	3,709.93	4,620.30	9,986.90

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Non-Current Assets	1,125.20	248.00	2,228.49	1,925.10	7,785.92
Current Assets	2,722.74	494.30	1,481.44	2,618.40	2,200.42
Total Assets	3,855.82	750.80	3,709.93	4,620.30	9,986.90
Total Debt*	29.59	0.00	95.13	0.00	2,083.91
Net Current Assets	2,195.65	365.90	576.85	1,532.20	275.63
Contingent Liabilities	--	1.50	97.31	--	423.42

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Cash From Operating Activities	458.13	174.80	509.13	650.80	375.23
Cash Flow from Investing Activities	-248.27	7.60	-395.41	-512.40	-192.21
Cash from Financing Activities	-70.93	-134.50	-123.68	-82.60	-102.09
Net Cash Inflow / Outflow	138.93	47.90	-9.96	55.80	80.93

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
ROCE (%)	21.10	98.11	20.97	18.92	2.31
ROE (%)	15.31	73.20	15.16	14.14	0.06
ROA (%)	11.85	37.26	10.09	10.31	0.03
EBIT Margin (%)	23.16	37.27	31.10	19.68	18.09
Net Margin (%)	13.85	26.77	15.39	11.20	0.12
Cash Profit Margin (%)	17.07	27.35	23.50	15.03	10.95

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Revenue Growth (%)	12.51	21.24	29.38	23.64	3.66
EBIT Growth (%)	14.07	15.44	53.37	7.72	55.90
Net Profit Growth (%)	9.79	32.65	105.08	-1.38	102.11
EPS Growth (%)	9.81	32.65	101.82	-1.79	102.11
Book Value Growth (%)	22.41	41.18	16.76	19.89	3.63

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Price / Earnings	17.04	43.36	58.91	26.06	1,053.24
Price / Book Value	2.36	27.11	8.29	3.38	0.59
Dividend Yield (%)	0.57	1.66	0.00	0.52	0.00
EV/EBITDA	9.02	30.65	30.12	14.57	10.17
Market Cap (₹ Cr)	7,121.50	10,410.62	20,554.39	10,450.76	3,411.88

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Debt to Equity	0.01	0.00	0.04	0.00	0.36
Short term debt to equity ratio	0.01	--	0.03	--	0.11
Current Ratio	5.17	3.85	1.64	2.41	1.14
Quick Ratio	3.32	3.37	1.47	2.41	0.68
Interest Coverage	24.24	161.15	12.40	28.20	1.12

	Marksans Pharma	Sanofi Consumer Healthcare India	Sai Life Sciences	Indegene	Dishman Carbogen
Debtors to sales (%)	21.84	3.37	17.04	27.97	24.53
Asset Turnover	0.86	1.43	0.63	0.90	0.28
Receivable days	71.16	8.58	60.56	90.10	77.38
Inventory Days	109.20	20.38	22.43	0.00	120.02
Payable days	91.82	118.89	194.31	--	172.74
Cash Conversion Cycle	88.55	-89.93	-111.32	--	24.66

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.